<div id="ectolysins-against-gram-negative-bacteria" class="gg-light">
  <div class="centerize ctz-lg px-3 py-5 gg-calypso-text anim-hidden fade-in-up">
    <h2 class="fw-900 text-center mb-4">Overcoming Gram-Negative Bacterial Infections</h2>
    <p style="font-size:1.4rem; line-height:2;">The development of ectolysins against Gram negative bacteria is a challenge due to the presence of an impermeable outer membrane that prevents access to the Gram negative peptidoglycan layer of the cell wall.</p>

	<p style="font-size:1.4rem; line-height:2;">GangaGen has successfully overcome this challenge to discover and engineer lysins with broad spectrum activity against human pathogens such as <em>Acinetobacter baumannii</em> and <em>Pseudomonas aeruginosa</em>.</p>

	<p style="font-size:1.4rem; line-height:2;">GangaGen's Gram negative ectolysins are potent in diverse <em>in vitro</em> studies including demonstrated activity in relevant biological fluids and <em>in vivo</em> studies. GangaGen aims to develop these ectolysins as an intravenous therapeutic for human applications.</p>
  </div>
</div>